Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-22T17:13:16.644Z Has data issue: false hasContentIssue false
  • English
  • Français

Two cases of risperidone-induced tardive dyskinesia and a review of the literature

Published online by Cambridge University Press:  16 April 2020

L. Lykouras ,
R. Yannakis ,
J. Hatzimanolis  and
G.N Christodoulou
Get access

Summary

A case in which a 26 year old patient with undifferentiated schizophrenia, showing abnormal oral, lingual and jaw movements suggestive of tardive dyskinesia during a dose reduction of risperidone, is presented. A second case, relating to a 39 year old married woman diagnosed as having a DSM-IV schizophreniform disorder is also presented. These two cases are discussed in relation to the existing literature.

Keywords

risperidonetardive dyskinesia
Type
Case report
Information
European Psychiatry , Volume 14 , Issue 4 , July 1999 , pp. 245 - 247
Copyright
Copyright © Elsevier, Paris 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–835.Google ScholarPubMed
Leyson, J, Gommeren, W, Ins, A. Biochemical profile of risperidone: a novel antipsychotic. J Pharmacol Exp Therapeutics 1988; 247: 661–670.Google Scholar
Nyberg, S, Farde, L, Eriksson, L, Halldin, C, Eriksson, B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 1993; 110: 265–272.CrossRefGoogle ScholarPubMed
Chouinard, G, Jones, B, Remington, G, Bloom, D, Addington, D, Macewan, GWet al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacology 1993; 13: 25–40.CrossRefGoogle ScholarPubMed
Umbricht, D, Kane, JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22: 475–483.CrossRefGoogle ScholarPubMed
Kopala, LC, Honer, WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacology 1994; 14: 439–441.CrossRefGoogle Scholar
Chouinard, G. Effect of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacology 1995; 15 Suppl 1: 36–44.CrossRefGoogle ScholarPubMed
Addington, DE, Towes, JA, Addington, JM. Risperidone and tardive dyskinesia (letter). Am J Psychiatry 1995; 56: 484–485.Google ScholarPubMed
Anand, VS, Dewan, MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 1996; 8: 179–182.CrossRefGoogle Scholar
Buzan, DR, Firestone, D, Thomas, M, Franklin, DA. Risperidone-induced tardive dyskinesia (letter). Am J Psychiatry 1996; 153: 734–735.Google ScholarPubMed
Daniel, GP, Smith, K, Hyde, T, Egan, M. Neuroleptic-induced tardive dyskinesia (letter). Am J Psychiatry 1996; 153: 734.Google ScholarPubMed
Feeney, DJ, Klykylo, W. Risperidone and tardive dyskinesia (letter). J Am Child Adolesc Psychiatry 1996; 35: 1421–1422.CrossRefGoogle ScholarPubMed
Woarner, MG, Sheitman, BB, Lieberman, JA, Kane, JM. Tardive dyskinesia induced by risperidont? (letter). Am J Psychiatry 1996; 153: 843Google Scholar
Hoberfellner, EM. Tardive dyskinesia during treatment with risperidone (letter). Pharmacopsychiatry 1997; 30: 271CrossRefGoogle Scholar
Gwinn, KA, Caviness, JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997; 12: 119–121.CrossRefGoogle ScholarPubMed
Sakkas, P, Liappas, J, Christodoulou, GN. Tardive dyskinesia due to risperidone. Eur Psychiatry 1998; 13: 107–108.CrossRefGoogle Scholar
Saran, BM. Risperidone-induced tardive dyskinesia (letter). J Clin Psychiatry 1998; 59: 29–30.CrossRefGoogle ScholarPubMed
Coulter, DM, Pillans, PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122–125.Google ScholarPubMed
Kane, JM, Smith, IM. Tardive dyskinesia: prevalence and risk factors 1959–1979. Arch Gen Psychiatry 1982; 39: 473–481.CrossRefGoogle Scholar
Kane, JMTardive dyskinesia: epidemiological and clinical presentation.In: Bloom, FE, Kupfer, AJ eds. Psychopharmacology the fourth generation of progress. New York: Raven Press; 1995. p. 1485–1495.Google Scholar
American Psychiatric Association Task Force on tardive dyskinesia. Tardive Diskinesia. Washington DC: American Psychiatric Association; 1992.Google Scholar
VanKammen, DP, Marder, SR. Dopamine receptors antagonists.In: Kaplan, HISadock, BJ eds. Comprehensive text book of psychiatry, 6th Baltimore: Williams and Wilkins; 1995. 1782–2022.Google Scholar
Gutierez-Esteinou, B, Grebb, JA. Risperidone: an analysis of the first three years in general use. Intern Clin Psychopharmacology 1997; 12 Suppl 4: 3–10.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.